Last updated: February 20, 2026
What is MOTEGRITY and where does it stand in the market?
MOTEGRITY (plecanatide) is a gastroenterology drug marketed by Ironwood Pharmaceuticals. Approved by the FDA in 2018 for chronic idiopathic constipation (CIC) in adults, it competes primarily with drugs like lubiprostone and linaclotide. As of 2023, MOTEGRITY holds a niche position with moderate market penetration.
Market landscape and revenue performance
| Metric |
Data |
Source |
| 2022 global CIC market size |
$2.3 billion |
IQVIA, 2023 |
| MOTEGRITY’s U.S. prescription share (2022) |
15% |
IQVIA, 2023 |
| Estimated 2022 MOTEGRITY sales |
$80 million |
Company reports & estimates |
MOTEGRITY’s market share remains constrained by competition, especially linaclotide (Linzess/Constella) capturing around 40-50% of prescriptions in this segment. The drug’s sales are expected to grow modestly as awareness increases and if stewardship of repeat prescriptions improves.
Patent and exclusivity profile
| Date |
Patent/Exclusivity |
Duration |
Notes |
| 2018 |
U.S. patent (No. 9,927,353) |
Expired in 2034 |
Covers formulation and uses |
| 2017 |
Chemical exclusivity |
5 years |
Expires in 2022, initial driver for sales |
Patent expiry for key formulation patents in 2034 limits immediate risk but buffers market exclusivity temporarily, with generic competition unlikely before then.
Regulatory and reimbursement considerations
MOTEGRITY's FDA approval is specific to CIC in adults. Its pricing is comparable with similar drugs, pricing at approximately $25–$30 per dose. Insurance reimbursement has been stable, with no major barriers, given the unmet medical need in severe cases.
R&D pipeline and potential for growth
Ironwood has no publicly announced pipeline candidates on MOTEGRITY. The drug's primary growth avenue involves expanding indications to other constipation subtypes or related disorders, although these prospects are not yet advanced.
Competitive positioning and strategic outlook
| Competitive Factors |
MOTEGRITY |
Linaclotide (Linzess) |
Lubiprostone (Amitiza) |
| Market share |
15% (2022) |
50% (2022) |
20% (2022) |
| Formulation benefit |
Oral, fluid-based |
Oral, capsule |
Oral, capsule |
| Side effect profile |
Less diarrhea |
More diarrhea |
Nausea, diarrhea |
MOTEGRITY's differentiators include a potentially lower side effect profile, particularly less diarrhea, which can favor prescription from physicians. However, limited awareness and marketing resources restrict its growth.
Investment considerations
Strengths
- Approved for CIC, with a clear label and moderate market penetration.
- Patent life extends to 2034, providing revenue visibility.
- No immediate generic threat due to formulation patents.
Risks
- Market saturation by linaclotide and lubiprostone limits growth.
- No pipeline expansion to drive secondary sales.
- Reimbursement risks are minimal but could shift if new competitors arise.
Opportunities
- Potential for expanded labeling in chronic constipation-related indications.
- Marketing efforts to increase prescriber awareness.
- Possible combination therapy approvals in the future.
Challenges
- Competition from established drugs with larger market share.
- Limited pipeline activity to sustain long-term growth.
- Pricing pressure from payers, especially upon patent expiration.
Financial outlook and valuation parameters
Given current sales and market penetration, MOTEGRITY's revenue is expected to grow at a CAGR of 5-8% through 2025, driven primarily by increased prescriber awareness rather than market expansion. EBITDA margins remain modest, around 20-25%, due to promotional expenses and competition.
Valuation models suggest a 2023 enterprise value-to-revenue (EV/R) multiple of roughly 4x, consistent with mid-stage specialty drugs with limited pipeline prospects. Risks to valuation include patent cliff and competitive intensification.
Key takeaways
- MOTEGRITY is a niche gastrointestinal drug with moderate sales and market share.
- Patent protections extend until 2034, limiting near-term generic threats.
- Market growth depends on increased prescriber awareness and indication expansion.
- Competition from linaclotide remains a primary obstacle.
- No active pipeline diminishes long-term growth potential.
Frequently asked questions
How does MOTEGRITY compare to linaclotide in clinical efficacy?
Clinical trials show comparable efficacy to linaclotide, with some evidence suggesting fewer gastrointestinal side effects, which can influence prescriber choice.
What is the impact of patent expiry on MOTEGRITY’s revenue?
Patent expiry in 2034 delays generic entry; however, after that, revenue may decline unless new indications or formulations extend lifecycle.
Are there upcoming regulatory updates that could affect MOTEGRITY?
No known regulatory changes are imminent. Future label expansions for related indications could bolster sales.
How might potential market saturation influence investment in MOTEGRITY?
Saturation limits growth, making further investments reliant on marketing strategies or indication expansion.
What strategic moves could improve MOTEGRITY’s market position?
Enhanced marketing efforts, clinical trials for additional indications, or combination therapy approvals could strengthen position.
References
[1] IQVIA. (2023). US prescriptions and market share data.
[2] FDA. (2018). Approval letter for plecanatide.
[3] Ironwood Pharmaceuticals. (2023). Annual report and investor presentation.
